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Background: Early screening for cancer is arguably one of the greatest public health advances over the last fifty
years. However, many cancer screening tests are invasive (digital rectal exams), expensive (mammograms, imaging)
or both (colonoscopies). This has spurred growing interest in developing genomic signatures that can be used for
cancer diagnosis and prognosis. However, progress has been slowed by heterogeneity in cancer profiles and the
lack of effective computational prediction tools for this type of data.
Results: We developed anti-profiles as a first step towards translating experimental findings suggesting that
stochastic across-sample hyper-variability in the expression of specific genes is a stable and general property of
cancer into predictive and diagnostic signatures. Using single-chip microarray normalization and quality assessment
methods, we developed an anti-profile for colon cancer in tissue biopsy samples. To demonstrate the translational
potential of our findings, we applied the signature developed in the tissue samples, without any further retraining
or normalization, to screen patients for colon cancer based on genomic measurements from peripheral blood in an
independent study (AUC of 0.89). This method achieved higher accuracy than the signature underlying
commercially available peripheral blood screening tests for colon cancer (AUC of 0.81). We also confirmed the
existence of hyper-variable genes across a range of cancer types and found that a significant proportion of
tissue-specific genes are hyper-variable in cancer. Based on these observations, we developed a universal cancer
anti-profile that accurately distinguishes cancer from normal regardless of tissue type (ten-fold cross-validation
AUC > 0.92).
Conclusions: We have introduced anti-profiles as a new approach for developing cancer genomic signatures that
specifically takes advantage of gene expression heterogeneity. We have demonstrated that anti-profiles can be
successfully applied to develop peripheral-blood based diagnostics for cancer and used anti-profiles to develop a
highly accurate universal cancer signature. By using single-chip normalization and quality assessment methods, no
further retraining of signatures developed by the anti-profile approach would be required before their application
in clinical settings. Our results suggest that anti-profiles may be used to develop inexpensive and non-invasive
universal cancer screening tests.
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Early detection through mass screening remains one of
the most effective approaches for reducing health care
costs [1-4] and mortality [5-10] due to cancer. Despite
the benefits, there remain significant barriers to cancer
screening including cost [11,12], lack of insurance
[11,13], and anxiety or embarrassment about invasive
procedures [11,12,14]. There are also cancer types for
which mass-screening tools have not been developed
[15,16]. Reducing the cost and inconvenience of screen-
ing may lead to increased early screening and potentially
improve patient and health economic outcomes.
Peripheral blood-based genomic signatures are a
promising avenue for developing non-invasive cancer
biomarkers [17-21]. However, lack of stable markers in
cancer gene expression profiles and associated blood
samples has made finding robust screening biomarkers
difficult. Here we take advantage of a new theoretical
model for evolutionary fitness that suggests that a defin-
ing characteristic of cancer is increased epigenetic and
gene expression variability [22]. Supporting evidence was
provided by the observation of increased variability in
DNA methylation across five different cancer types [23].
This model implies that a stable characteristic is that
certain genes will consistently show higher across-
sample variability in cancer as compared to normal sam-
ples. We present a statistical technique that leverages
this characteristic by identifying genes that show normal
variation in healthy samples, but hyper-variability across
tumor samples and use these genes to predict outcome
using what we refer to as an anti-profile. We define an
anti-profile score for a specific sample as the number of
hyper-variable genes for which expression in that sample
falls outside a defined range of normal expression (see
Methods for details). We illustrate the technique on a
colon cancer dataset, suggest its potential by predicting
cancer in a peripheral blood dataset, and explore the
possibility of a universal cancer predictor by simultan-
eously predicting outcome with data from 52 cancer
types. All datasets were obtained from public
repositories.
We complement our novel statistical approach with
new biological insights related to cancer. For the colon
cancer anti-profiles we incorporate the finding that con-
sistent decreases in methylation are observed along large
(5kb – 10Mb) genomic blocks [23]. Specifically, we only
considered genes that lie inside these blocks for the
colon cancer anti-profile. For the universal anti-profile
we incorporated the finding that genes showing epigen-
etic hyper-variability in cancer tend to be tissue specific
genes [23-25]. We therefore restricted genes in our uni-
versal cancer anti-profile to tissue-specific genes.
Gene expression variability and stochasticity have been
studied previously in the context of normal populations[26,27], with recent work exploring the role of genetic
variants in altering expression variation and stochasticity
[28]. Of particular interest is recent work showing a link
between variation in normal populations and HIV sus-
ceptibility [29]. It is only recently, however, that direct
association between gene expression variability and dis-
ease has been studied on neurological disease [23,30]
and cancer [23]. We show that increased variability in
specific genes is a characteristic feature in many cancer
types that can be used for prediction. The anti-profile
method we propose here is an application to the predict-
ive setting of ideas in existing statistical methods devel-
oped to identify and model outliers in gene expression
due to cancer [31,32]. Here we expand these ideas and
leverage our knowledge of and experience with prepro-
cessing and normalization of high-throughput expres-
sion data to describe and demonstrate the effectiveness
of the anti-profile method to develop signatures based
on technology ready to be used in clinical settings
(through quality assessment and normalization) and a
general and stable cancer marker (increased gene ex-
pression hypervariability of specific genes).
Results and discussion
Gene expression anti-profiles
We developed the anti-profile method as a simple and
robust approach to define cancer genomic signatures by
specifically taking advantage of heterogeneity in cancer.
An important first step in our approach is to normalize
raw gene expression data; an often-overlooked, but key
issue in the development of genomic signatures based
on microarray data. Standard microarray normalization
methods cannot be used when developing clinical diag-
nostics since they require multiple samples and normal-
ized values depend on which samples are normalized
together [33,34]. This means that signatures can only be
translated to the clinic after independent retraining of
the signatures is performed with single-sample
normalization techniques [35]. For all signatures devel-
oped here, we employ a recently developed single-
sample normalization technique for microarrays [36]
and a single-array quality metric [37]. Since signatures
are developed with single-sample normalization, they
can be directly used as clinical diagnostics, without fur-
ther retraining.
To illustrate our method we developed an expression
anti-profile that distinguishes colon cancer from normal
colon in tissue biopsies. We used two independent colon
cancer studies, performed by different groups [38-40], as
an example. We designated one of these datasets as a
training set [38,39] and looked at genes inside reported
colon methylation change blocks [23] to select those that
showed hyper-variability within colon cancer samples
compared to normals. This dataset [38,39] includes
Corrada Bravo et al. BMC Bioinformatics 2012, 13:272 Page 3 of 11
http://www.biomedcentral.com/1471-2105/13/272premalignant lesions (adenomas) which we treated as a
separate biological class and were not included in the
following analysis. We applied the resulting anti-profile
signature on the independent testing colon cancer data-
set in biopsies [40] to evaluate its accuracy and observed
area under the ROC curve (AUC) of 0.94 (Figure 1B)
with 76% accuracy. We also performed the same experi-
ment with training and testing sets reversed and
obtained an AUC of 1.0 with 86% accuracy. We found
that the normal ranges of expression defined independ-
ently by the two colon cancer experiments were stable
(Figure 1C), consistent with the observation that these
genes are tightly regulated in normal tissue.
To determine the relationship between gene expres-
sion hyper-variability and CpG DNA methylation hyper-
variability, we examined a publicly available DNA
methylation dataset comparing colon cancer with
matched normal colon tissue on the Illumina Human-
Methylation 27k BeadChip array (see Methods). We
found that there is significant overlap between genes
with hyper-variable expression in colon cancer and pro-
moter region CpG hyper-variable methylation (Fisher’s
exact test OR=2.41, P=0.005, see Methods). We then
repeated the experiment on the two colon cancerA
Figure 1 The colon cancer anti-profile signature. (A) Normalized gene
independent colon cancer datasets [38-40]. Normal samples are shown in g
as the set of genes and a corresponding range of normal expression value
methylation blocks [23] were included. The anti-profile score for each samp
defined range of expression. Blue circles highlight expression for one speci
the anti-profile method trained on one colon cancer study to score sample
genes inside colon DNA methylation change blocks where across-sample v
The anti-profile method is very accurate (ROCs of 0.94 and 1.00). (C) We co
absolute deviation) as defined by the two independent colon cancer studiexpression datasets using CpG hyper-variable methyla-
tion to select anti-profile genes and observed worse pre-
diction performance (AUC=.84 and AUC=.97).
Enrichment of hyper-variable CpG DNA methylation in
blocks of hypo-methylation for this dataset has been
previously reported [23]. Considering the reduced cover-
age of the 27k array, which is biased towards CpG
islands, this prediction result indicates the advantage of
using hypo-methylation blocks in cancer as a stable and
comprehensive proxy for methylation hyper-variability in
the absence of suitable direct measurements.
Colon cancer biomarker in peripheral blood
We combined the two colon-cancer tissue datasets
described above and derived one anti-profile signature
(542 genes). We directly applied the anti-profile derived
from colon tissue to publicly available peripheral blood
samples that passed quality assessment (see Methods
section for details) from cancer patients (n=15) and nor-
mal samples (n=15) without any retraining [19]. We
were able to accurately identify colon cancer samples
from peripheral blood (AUC 0.89, Figure 2 and Add-
itional file 1: Figure S1). Without retraining, the accur-
acy of our anti-profile signature was equivalent to theB
C
expression for 15 hyper-variable genes in cancer from two
reen, cancer samples are shown in orange. We define the anti-profile
s for each gene (indicated by dotted lines). Only genes inside colon
le is the number of genes in the signature that are outside their
fic cancer sample with an anti-profile score of 9. (B) ROC curves using
s from an independent colon cancer study. The anti-profile includes
ariance in cancer is at least twice that of normal in the training study.
mpare the upper bounds of normal expression (median + 5*median
es and find that ranges are highly consistent.
A B
Figure 2 The colon cancer peripheral blood anti-profile. (A) Plot of the anti-profile scores calculated with the colon tissue anti-profile on an
independent peripheral blood study without retraining [19]. (B) ROC curve and AUC value for the anti-profile prediction on the independent
peripheral blood study. The anti-profile method achieves an AUC of 0.89 without any retraining.
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oped by Han et al. [19] directly on these blood samples
(AUC =0.88). Estimated training-set accuracy is known
to be an overestimate of the true out of sample accuracy
for a signature[41], so we also tested the five-gene signa-
ture using logistic regression and found its leave-one-out
AUC to be 0.81 (P-value=0.19 for test of differences be-
tween this and the AUC for the anti-profile signature).
We note that further optimization of our anti-profile for
this task is possible by selecting the optimal number of
genes based on performance on the peripheral blood
samples themselves. For instance, a slightly larger anti-
profile signature (650 genes) achieved an AUC of 0.93
(Additional file 1: Figure S1, P-value=0.08 for test of dif-
ferences between AUCs). However, this type of
optimization should be based on datasets with more
samples than available here and thus we didn’t pursue
this avenue further.
Consistent hyper-variability across cancer types
We collected and manually curated a set of 6,172 cancer
and normal microarray samples in biopsies (n=4,950 and
n=1,222 respectively) from 59 tumor types and 102 nor-
mal tissue types across 176 different studies in the Gene
Expression Omnibus (GEO, [42]). Additional file 1:
Table S1 lists the GEO accession number of experiments
included in the dataset after removing samples that did
not pass the single-chip quality filtering criteria, along
with the tissue or tumor type and clinical characteristics
annotated in each experiment. These data represent all
the clinical information available about each of these
samples in GEO. For each tissue or tumor type the num-
ber of biological replicates varied and for seven tissue
types (adrenal cortex, colon, endometrium, kidney, skin,
stomach and vulva) we had at least 10 samples of each
of normal tissue and corresponding tumor type.
Using these data we developed an anti-profile to pre-
dict cancer status regardless of tumor or tissue type.First, we confirmed that across-sample variability was a
general characteristic of cancer (Additional file 1: Figure
S2). We selected hyper-variable genes and defined nor-
mal ranges as described above (details on the few tech-
nical differences are described in the Methods section).
Looking at the top 100 genes that showed consistent
hyper-variability in cancer we found they were consist-
ently unexpressed in most normal tissues while consist-
ently expressed in a few normal tissues (Figure 3A). In
contrast, no consistency of expression was observed in
cancer (Figure 3A). We observed the same pattern on an
independent set of samples not used to define hyper-
variable genes (Additional file 1: Figure S3). We con-
firmed that hyper-variable genes in cancer coincide with
tissue specific genes (Figure 3B and C, Additional file 1:
Figure S4). Specifically, we found that the set of tissue-
specific genes were enriched for universally hyper-
variable genes (Fisher test, odds-ratio 3.1, P<2.2e-16,
Additional file 1: Figure S5). Gene ontology category en-
richment analysis [43] performed on the anti-profile
genes found that categories involving development,
organ morphogenesis and differentiation are enriched
with hyper-variable genes (Additional file 1: Table S2).
Consistent hyper-variability across cancer is not due to
cellular heterogeneity
Our results suggest that the universally consistent gene
expression hyper-variability we report here cannot be
fully ascribed to cellular heterogeneity in cancer samples.
For a gene to show hyper-variability in cancer due to
cellular heterogeneity, it must also be a marker for a
number of distinct cell types in a heterogeneous cellular
mixture found in a tumor. However, we found that a
large number (45%) of universally hyper-variable genes
in cancer are not consistently expressed in any of the
normal tissues in our dataset (we say a gene is consist-
ently expressed for a tissue if it is expressed in at least
95% of the normal samples for that tissue, see Methods
A B
C
Figure 3 Genes with consistent hyper-variability across cancer types. (A) The 100 genes that most consistently show hyper variability across
cancer types. We first define a normal range of expression using normal samples across all tissue types expecting that normal samples from a few
tissue types will deviate from this normal range due to the tissue specificity of some genes. Each cell in the matrix indicates the percentage of
samples of each type in which expression is outside the normal range. We observed that for the majority of genes, the percentage of samples in
each normal tissue type outside normal range is close to either 0% (most tissues) or 100% (the small number of tissues for which the gene is
specific). We also observed that in cancer, percentages are consistently away from 0% or 100%, indicating high variability. (B) Principal
components for normal samples in adrenal cortex, colon, endometrium, kidney, skin, stomach and vulva. Circles illustrate profiles of normal
expression for each tissue type. (C) Principal components for cancer samples. Increased variability is present in cancer but not manifested as
multiple tightly defined sub-groups for each cancer type. Instead, we observe lack of regulation in cancer around tightly regulated regions of
normal expression in each tissue type. The anti-profile method is based on this observation: stochastic departure from tightly regulated normal
expression in these genes is characteristic in cancer and can be used in predictive settings.
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sally hyper-variable genes in cancer, hyper-variability
cannot be the result of a heterogeneous mixture of mar-
kers for different cellular subtypes since these genes are
usually silenced in normal tissues. Also, while hyper-
variable genes are enriched in the set of tissue-specific
genes, we found that the majority of tissue-specific genes
are not consistently hyper-variable (64%). The vast ma-
jority of tissue-specific genes show hyper-variability in a
small number of cancer types (Additional file 1: Figure
S6) as expected from a histologically heterogeneous
sample. This suggests that the lack of regulation of the
particular tissue-specific genes that are consistently
hyper-variable across cancer types represents a specific
and general characteristic of cancer.
We also investigated the relationship between cancer-
specific hyper-variability and tissue-specificity in the
seven tissues for which we have sufficient samples ofboth normal and cancer. We found that the vast major-
ity (95-99%) of hyper-variable genes in each of these
cancers are not tissue-specific for the corresponding
normal tissue (Additional file 1: Table S5). However,
hyper-variable genes in each of these cancers are
enriched in the set of genes that are specific for the cor-
responding normal tissue, although the number of genes
is small. This small set of genes could indeed include
those where hyper-variability in that specific cancer is
due to cellular heterogeneity, as normal cells may be
included in varying proportions in these tumor samples.
We looked at the relationship between cancer-specific
differential expression, determined using Empirical
Bayes methods [44] as fold-change greater than 1 and
significance less than 10% FDR, and tissue-specificity in
the same seven tissues. Similar to hyper-variability we
found that the vast majority of differentially expressed
genes in each of these cancers are not tissue-specific for
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to hyper-variable genes there is no enrichment of differ-
entially expressed genes in the set of genes that are spe-
cific for the corresponding normal tissue.
Considering this finding, we investigated the relation-
ship between cellular-specificity and the colon cancer
peripheral blood result reported above. We determined
genes that are specific to strictly one of two types of
lymphocytes for which we had five or more samples in
our dataset (CD4+ and CD31+ T-cells) and found that
12% of the genes used in the peripheral blood colon can-
cer anti-profile fall under this category. Furthermore,
lymphocyte-specific genes are enriched in the set of
genes with hyper-variable expression in colon cancer in-
side colon cancer hypo-methylation blocks (Fisher’s
exact test OR 3.0, P=1.2e-11). This suggests that we can-
not rule out that varying lymphocyte composition in the
peripheral blood samples of colon cancer patients may
drive the prediction performance of the peripheral blood
anti-profile.
Universal cancer anti-profile
While in the colon cancer anti-profile we restricted
genes to be in the colon-cancer hypo-methylated blocks
here we used our newly found biological insight: we
restricted the anti-profile to tissue-specific genes defined
as those genes that are expressed in at least 95% of sam-
ples for at most three tissues using the gene expression
barcode method [45]. With an anti-profile classification
in place, we then quantified the accuracy of this univer-
sal anti-profile method by performing two cross-
validation experiments. We first performed a 10-fold
cross validation experiment where an anti-profile was
constructed on the training set of each cross-validation
fold. The procedure was highly accurate with an average
area under the ROC curve (AUC) across the 10 cross-
validation experiments of 0.92 (Figure 4A). We next per-
formed a novel leave-one-tissue out cross-validation ex-
periment. For each of the seven tissues for which we had
both normal and cancer samples, we defined an anti-
profile using samples from the other six tissues and
scored samples from the tissue being tested (Figure 4B
and C). For all experiments, the leave-one-tissue-out
anti-profiles achieved AUCs greater than 0.87. We also
observed that the set of probes consistently selected
across cross-validation experiments is very stable, indi-
cating the robustness of the anti-profile procedure (Add-
itional file 1: Figure S7). Our analysis indicates that the
anti-profile method is able to accurately distinguish
tumors from normal samples on tissues not included in
its training set and further suggests the universal applic-
ability of the anti-profile method.
We used pathological tumor stage or grade annotation
available for a subset of the samples used in the leave-one-tissue-out cross-validation experiment to determine
if heterogeneity across samples in pathological tumor
stage or grade may explain the increased gene expres-
sion variability observed in anti-profile genes used for
prediction. For each of the leave-one-tissue-out experi-
ments reported in Figure 4, we used an F-test to find
genes that are differentially expressed across pathological
stages or grades (FDR<0.1, Additional file 1: Table S6).
We then applied a Fisher exact test to determine if the
100-gene anti-profile signature used in the leave-one-
out-tissue experiment overlapped this set of differentially
expressed genes. We found very few genes that are dif-
ferentially expressed across pathological tumor stage or
grade for adrenal cortex, stomach and vulva (22, 2 and 4
respectively). For the remaining experiments no substan-
tial overlap was observed (OR<2, P-value<0.05). This
suggests that increased gene expression variability in
anti-profile genes is not explained by heterogeneity of
pathological tumor stage or grade in our samples.
Conclusions
We have introduced and developed gene expression
anti-profiles for cancer biomarker discovery. Anti-
profiles explicitly model increased gene expression vari-
ability in cancer to define robust and reproducible gene
expression signatures capable of accurately distinguish-
ing tumor samples from healthy controls. We have
developed an anti-profile signature in tissue samples
from a colon cancer study and validated our signature in
a second independent validation set, collected by a dif-
ferent experimental group. We have also applied this sig-
nature directly, without retraining, to classify patients
with cancer from normals on the basis of genomic mea-
surements in peripheral blood.
We note that Mammaprint [46,47], one of the most
successful genomic cancer biomarkers, fits our notion of
an anti-profile: its score is calculated based on the cor-
relation between the test sample and a good prognosis
gene expression profile. The failure of other, more com-
plex genomic methods to outperform Mammaprint may
be due to their reliance on defining specific cancer pro-
files [48]. While both Mammaprint and our anti-profile
method classify samples based on deviation from a refer-
ence profile, there are two significant differences in the
way Mammaprint and the anti-profile method achieve
this: 1) Mammaprint uses tumor samples with good
prognosis to determine the reference profile. Since these
are tumor samples many of the genes used in the profile
may exhibit high variability across the good prognosis
group. Defining a stable and robust reference profile is
essential to the success of this type of method. 2) Mam-
maprint uses correlation to measure how samples devi-
ate from the reference profile. Our anti-profile method
instead uses a robust measure where deviation is based
AC
B
Figure 4 A stochastic universal cancer classifier. (A) ROC curves for a 10-fold cross-validation experiment classifying any sample as normal or
tumor, where the anti-profile is trained (genes selected and normal regions of expression defined) independently for each fold, and the ROC is
computed for each testing fold independently. (B) ROC curves for 7 leave-one-tissue-out experiments. In each of the leave-one-tissue-out
experiments, all samples of that particular type (both normal and tumor) are removed from training sets and then scored using the resulting anti-
profiles. (C) Cross-validated anti-profile scores for the 7 leave-one-tissue-out experiments. The anti-profile scores can separate a large number of
tumors from their corresponding normal samples.
Corrada Bravo et al. BMC Bioinformatics 2012, 13:272 Page 7 of 11
http://www.biomedcentral.com/1471-2105/13/272on the number of the genes for which expression falls
outside normal ranges of expression, which are them-
selves estimated using robust methods. It may be pos-
sible to improve on the accuracy of the Mammaprint
test by adopting a more robust anti-profile based on the
methods presented in this paper.
In this case we can use the anti-profile score, that is,
the number of genes in the anti-profile where expression
deviates from a normal range of expression obtained
from normal breast tissue samples, to determine prog-
nosis. Since this score is based on stable expression in
normal tissues, it may be more robust than calculating
correlation to a mean signature for tumors with good
prognosis that would show high variability. This willrequire that more samples of both normal breast tissue
and tumor are available on platforms for which robust,
single-chip normalization methods exist.
In addition to developing a peripheral blood signature
for colon cancer, we have confirmed the existence of
hyper-variable genes across 59 distinct cancer types. We
also provide evidence of the close relationship between
hyper-variability across cancer types and tissue-specific
gene expression. Consistent with these observations on
tissue-specificity, gene ontology category enrichment
analysis found that categories involving development,
organ morphogenesis and differentiation are enriched
with hyper-variable genes and the remaining gene cat-
egories enriched with hyper-variable genes involved
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sion, localization and collagen catabolic processing or in
cell locomotion and cellular component movement.
These results argue strongly against the observed hyper-
variability being a consequence of sample heterogeneity
in the cancer samples.
Incorporating this general result on tissue-specificity
and hyper-variability we developed anti-profiles able to
classify tissue samples across multiple tissue and cancer
types, even when a specific cancer/tissue type is not
included in the original training set. Our cross-validation
results suggest that consistent hyper-variability of a small
set of tissue-specific genes is a stable mark of cancer
across tissue types. Our results also suggest the potential
for developing peripheral blood signatures for cancer
diagnostics on the basis of anti-profiles.
In the course of achieving these results we have used
recently developed statistical preprocessing methods to
remove potential artifacts in a way that is applicable to
single clinical samples[36]. This is a somewhat unique
approach, as genomic signatures are typically derived
after applying population-level pre-processing such as
RMA or artifact removal such as surrogate variable ana-
lysis. That we achieve such high accuracy in public data
– known to be subject to a broad range of technical and
biological artifacts[37] – speaks to the strength of our
methods.
Methods
Gene expression Affymetrix microarray data
preprocessing
We downloaded CEL files for 6,172 Affymetrix
HGU133plus2 microarrays from 176 studies in the Gene
Expression Omnibus (GEO, [42]). CEL files were prepro-
cessed with the frma ([36]) single-chip procedure. Ex-
pression measurements were standardized using Gene
Expression Barcode z-scores ([45]). We removed arrays
that were deposited multiple times into the repository
(Euclidean distance between arrays less than 1). We used
the GNUSE metric ([37]) to assess array quality and
removed all arrays from studies with median GNUSE
greater than 1.25 and removed individual arrays with
GNUSE greater than 1.2. We did further hand curation
to retain only normal tissue and cancer samples (n=688
and n=4,138 respectively). Additional file 1: Table S1
contains the complete list of studies and samples used in
the reported analyses including the type of clinical anno-
tation available for each sample. The curated and pre-
processed data is available for download at http://cbcb.
umd.edu/~hcorrada/antiProfiles.
Colon cancer anti-profile
We used the HGU133plus2 probeset annotation from
Ensembl (version 15, gene dataset version: GRCh37.p5)to map probesets to genes and obtain each gene’s tran-
scription start site. In the colon cancer anti-profile, we
only consider probesets for genes with transcription start
sites inside blocks of DNA methylation change ([23],
genomic coordinates available at http://www.nature.
com/ng/journal/v43/n8/extref/ng.865-S2.xls). We use
the ratio of standard deviations across samples as a stat-
istic to select probesets for the anti-profile: rg = log 2(Sgc/
Sgn)where sgc is the across-sample standard deviation of
expression for probeset g among the colon tumor sam-
ples, and sgn is the across-sample standard deviation of
expression for probeset g among the normal samples.
The anti-profile includes probesets with rg>1 (variability
in cancer is twice that of normal).
Normal regions of expression are defined for each pro-
beset as median expression +/− 5 median absolute
deviations of expression in the normal samples. We
found that our results are quite insensitive to the choice
of median absolute deviation multiplier (Additional file
1: Figure S8). The anti-profile score for a specific sample
is then the number of probesets outside their respective
range of normal expression. A cutoff score can be used
to turn the anti-profile score into a classification: scores
greater than the cutoff are classified as cancer, scores
lower than the cutoff are classified as tumor. A specific
cutoff can be determined according to a prescribed ob-
jective: e.g. maximize accuracy, or maximize specificity
at a given sensitivity in a held-aside test set. We used
area under the ROC curve [49] to measure anti-profile
accuracy and the DeLong method [50] as implemented
in the pROC package [51] to test for differences in AUC.
Colon cancer illumina HumanMethylation 27k array
We downloaded a publicly available dataset of methyla-
tion levels of 22 matched colon normal/tumor samples
assayed using Illumina’s HumanMethylation 27k array
(GEO accession number GSE17648). Methylation mea-
surements were used with no further preprocessing. Dif-
ferences in methylation variability were determined
using an F-test and significance determined at 1% false
discovery rate. For each probeset in our expression data
we found the CpG inside it’s promoter region (defined
as 1000bp upstream and 250bp downstream) nearest to
the transcription start site. We determined significant
expression hyper-variability using an F-test at 1% false
discovery rate to determine overlap between expression
hyper-variability and DNA methylation hyper-variability.
Colon cancer peripheral blood data
We obtained peripheral blood Affymetrix HGU133plus2
samples from colon cancer patients and healthy controls
([19] from the study authors, and [52] from GEO with
accession number GSE10715). Arrays were preprocessed
with fRMA and normalized using the gene expression
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which left 15 colon cancer samples and 15 normal sam-
ples from the first study. Median GNUSE for the second
study was 1.46 and thus was not included in the analysis
(all but three cancer samples had GNUSE >1.2 in this
study).
Colon cancer peripheral blood anti-profile signature
We defined the anti-profile from colon tissue by com-
bining samples from the two colon cancer biopsy data-
sets used in the Gene Expression Antiprofiles Results
section [38,40,52]. Probesets were included in the anti-
profile and regions of normal expression defined as
described above. No retraining was done to test on the
blood dataset. The list of genes and corresponding me-
dian and median absolute deviation of expression are
given in Additional file 2: Table S3.
To assess the sensitivity to signature size of the accur-
acy of the peripheral blood signature, we tested signa-
tures of increasing size with genes included in order of
decreasing hyper-variability across colon tumor samples
(Additional file 1: Figure S1). While the signature
reported in the manuscript obtained an AUC of 0.89,
similar AUCs are obtained with signatures with about
500–2000 genes inside blocks indicating that the predic-
tion result reported in the manuscript is not very sensi-
tive to the specific signature size chosen. To ascertain
significance of the prediction results obtained we per-
formed a randomization test: for each signature size, we
generated 1000 signatures with randomly selected sub-
sets of genes of the appropriate size to build each anti-
profile. Ranges of normal expression do not change since
these are defined from the colon tissue dataset. We used
the proportion of random signatures obtaining an AUC
greater than or equal to the anti-profile of the corre-
sponding size as a measure of uncertainty. Results that
showed significantly high AUC were signatures that in-
clude about 500–2000 of the top hyper-variable genes
inside methylation blocks.
Universal hyper-variable genes in cancer
To determine probesets that exhibit hypervariable ex-
pression in cancer we compute a variance ratio statistic
across multiple tissues. We restrict this computation to
tissues and cancer types with more than 10 samples in
our dataset (list given in Figure 3). We compute stand-
ard deviation of expression for probeset g (sgt) separately
for each tissue t and cancer type c (sgc). We define the
variance ratio statistic ug (Additional file 1: Figure S2) as
ug = log 2(meancsgc/meantsgt).
To define the universal normal range of expression we
use a similar method: we compute median expression
for each gene g on each tissue t separately (mgt) along
with median absolute deviation (madgt). The universalrange is then defined as mg +/− 5 * madg where mg=me-
diant(mgt) and madg=mediant(madgt). The list of hyper-
variable genes (ug>1) and associated median expression
and median absolute deviation of expression are pro-
vided in Additional file 3: Table S4.
Defining tissue-specific genes
To define tissue-specific genes, we tabulated the number
of samples in which a gene is expressed (defined as gene
expression barcode z-score greater than 2.54) for each
tissue in our dataset with more than 10 normal samples.
Tissue-specific genes were defined as those in which the
gene is expressed in more than 95% of the samples of at
most three tissues. Fisher’s exact test was used to deter-
mine enrichment of hyper-variable genes in the set of
tissue-specific genes (Additional file 1: Figure S5).
Gene ontology category enrichment analysis
Gene ontology (GO) enrichment analysis was done using
a hyper-geometric test for association between hyper-
variable genes (defined as ug>1) and GO terms. We used
the implementation in the Bioconductor GOstats pack-
age ([43]). We used the q-value ([53]) method to control
for multiple hypothesis testing and report enriched cat-
egories with Q<0.05 in Additional file 1: Table S2.
Cross-validation experiments
We performed two types of cross-validation experiments
to quantify the accuracy of universal cancer anti-profiles.
The first was ten-fold cross validation, data was ran-
domly split into 10 equal-sized subsets, retaining the
proportion of normal and cancer samples from the full
dataset in each subset. Each of the 10 subsets (or folds)
was used sequentially as a test set, scored using an anti-
profile trained on the remaining 90% of the data (this
includes all steps: 1) filtering to include only tissue-
specific probesets, 2) computing the universal variance
ratio ug, 3) selecting the top 100 genes based on the
ratio statistic, and 4) computing the universal normal
range of expression).
The other type of cross-validation experiment was car-
ried out on the 7 tissues for which we had at least 10
samples each of normal tissue and tumor. For each tis-
sue type, we performed a leave-one-tissue-out experi-
ment by using all samples (normal and corresponding
tumor type) as test set and scored them using an anti-
profile trained on the remaining data. This ensures that
no samples from the corresponding tissue (normal or
cancer) are included in the training set. Again, all steps
required to train the anti-profile were done completely
for each leave-one-tissue-out fold.
To classify a new sample we count the number of
anti-profile genes for which their expression fell outside
their normal range (Figure 2A). A large number of genes
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http://www.biomedcentral.com/1471-2105/13/272with expression outside the normal range, corresponding
to a high anti-profile score, are indicative of cancer. To
develop a predictor for new samples, a cutoff must be
defined on the number of genes outside the normal
range. If the anti-profile score is less than the cutoff, the
sample is classified as normal, if it is greater than cutoff
then the sample is classified as cancer.
Additional files
Additional file 1: Supplementary Material. This file contains
supplementary Figures and Tables.
Additional file 2: Table S3. Colon cancer anti-profile. Contains
Affymetrix probeset ids and normal expression median and median
absolute deviation.
Additional file 3: Table S4. Universal cancer anti-profile. Contains
Affymetrix probeset ids and normal expression median and median
absolute deviation.
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